4,6-二羟基-5-硝基吡啶-3-羧酸乙酯 | 6317-97-1

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4,6-二羟基-5-硝基吡啶-3-羧酸乙酯
• 英文名称: ethyl 2,4-dihydroxy-3-nitropyridine-5-carboxylate
• 英文别名: ethyl 4,6-dihydroxy-5-nitronicotinate；4,6-dihydroxy-5-nitro-nicotinic acid ethyl ester；4,6-Dihydroxy-5-nitro-nicotinsaeure-aethylester
• CAS: 6317-97-1
• 化学式: C₈H₈N₂O₆
• 分子量: 228.161
• InChiKey: JBTWWCUXSHUDEJ-UHFFFAOYSA-N

物化性质

• 熔点：
  243-246°
• 沸点：
  325.7±42.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4,6-二羟基-5-硝基吡啶-3-羧酸乙酯 在 镍 氨 、 水 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 180.0h， 生成 4-amino-1-[3-hydroxy-propyl]-1H-imidazo[4,5-c]pyridine-7-carboxylic acid ethyl ester
  参考文献：
  名称：

  WO2008/17696

  摘要：

  公开号：
• 作为产物：
  描述：

  4,6-二羟基烟酸乙酯 在 硫酸 、 硝酸 作用下， 生成 4,6-二羟基-5-硝基吡啶-3-羧酸乙酯
  参考文献：
  名称：

  Inhibitors of HIV-1 reverse transcriptase

  摘要：

  本发明提供了用于治疗或预防HIV感染，治疗艾滋病或ARC的化合物，包括根据公式I和II给予化合物，其中Q，R1，R2和R3如本文所述定义。

  公开号：

  US20100056535A1

文献信息

• [EN] NEW MACROLIDES AND THEIR USE<br/>[FR] NOUVEAUX MACROLIDES ET LEUR UTILISATION
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2009106419A1

  公开（公告）日：2009-09-03

  The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

  本发明涉及公式(I)的大环内酯化合物，以及所述化合物作为药物的应用，特别是用于治疗或预防炎性和过敏性疾病，包含所述化合物的药物组合物，以及它们的制备过程。本发明特别涉及主要通过抑制磷酸二酯酶4（PDE4）介导抗炎活性的大环内酯化合物，这使得它们可用于治疗和/或预防诸如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、特应性皮炎、炎症性肠病或增殖性疾病，例如癌症等炎性和过敏性疾病。
• The synthesis of a series of 7-amino-1-cyclopropyl-8-fluoro-1,4-dihydro-4-oxo-1,6-naphthyridine-3-carboxylic acids as potential antibacterial agents
  作者：Joseph P. Sanchez、Rocco D. Gogliotti

  DOI：10.1002/jhet.5570300402

  日期：1993.7

  xo-1,6-naphthyridine-3-carboxylic acids has been prepared and evaluated for antibacterial activity. These compounds were prepared by the displacement of the chloro substituent from 7-chloro-1-cyclopropyl-1,4-dihydro-8-fluoro-4-oxo-1,6-naphthyridine-3-carboxylic acid employing the requisite nitrogen nucleophile to produce the title compounds. The naphthyridine acid was synthesized in ten steps from

  已经制备了一系列的7-氨基-1-环丙基-1，4-二氢-8-氟-4-氧代-1，6-萘啶-3-羧酸，并评估了其抗菌活性。这些化合物是通过使用必要的氮亲核试剂从7-氯-1-环丙基-1,4-二氢-8-氟-4-氧代-1,6-萘吡啶-3-羧酸中取代氯取代基而制得的产生标题化合物。萘啶酸由2，4-二羟基-3-硝基-5-吡啶甲酸乙酯经十个步骤合成。序列中的关键步骤是使用衍生自3-氨基-2,4-二氯-5-吡啶甲酸乙酯的重氮鎓离子的六氟磷酸盐进行的Schiemann反应。
• Macrolides Useful Against Inflammatory and Allergic Diseases
  申请人：Kellenberger Johannes Laurenz

  公开号：US20100120706A1

  公开（公告）日：2010-05-13

  Macrolide compounds of formula I: with PDF4 inhibiting activity are described, wherein R1 is a residue —Y—X-Q; Y is S, SO or SO 2 ; X is a bond or a linear group consisting of hydrogen atoms and with up to 9 atoms selected from C, N, O and/or S, of which up to 2 atoms can be N and one atom can be O or S, one carbon atom can appear as a CO group and the sulphur atom can appear as an SO2 group and two adjacent C atoms can be present as —CH═CH— or —C≡C— and which group X is unsubstituted or is substituted with —COO—W or —CONH—W; Q is a residue —V-A1-L-A2-W or, if X does not represent a bond, may also be —NR6R7; V is a divalent aromatic or heterocyclic group; W is aryl or heterocyclyl; or in a group —V-A1-L-A2-W, wherein at least one of the groups A1; L or A2 is present, can also be a monovalent substituted or unsubstituted, saturated or unsaturated linear group with up to 5 atoms consisting of C, N, O and/or S of which one carbon can appear as a CO group one sulphur atom can appear as an SO2 group, A1, A2 are independently of each other either absent or a C 1 -C 4 alkylene group; L is —O—, —S—, —SO2-, —NH—, —CO—, —(CO)O—, —O(OC)—, —(CO)NH—, —NH(CO)—, —(SO 2 )NH—, —HN(SO 2 )—, —HN(CO)NH—, —O(CO)NH—, —NH(CO)O—, or can also be absent if A1 and/or A2 are present; R2 is hydrogen and R3 is and OR4 or R2, R3 taken together form a C═O group; R4 is hydrogen or an saturated or unsaturated aliphatic group with 1 to 6 carbon atoms; R6, R7 are independently selected from aryl; aralkyl; heterocyclyl and heterocyclylalkyl; and one of R6 and R7 can also be a group -L-W; and * indicates a chiral centre which is in the (R) or (S) form.

  本文描述了具有PDF4抑制活性的公式I的大环内酯化合物，其中R1是一个残基-Y-X-Q; Y是S，SO或SO2; X是一个键或由氢原子组成的线性基团，其中可选的原子有C，N，O和/或S，其中最多有2个原子可以是N，一个原子可以是O或S，一个碳原子可以出现为CO基团，硫原子可以出现为SO2基团，两个相邻的C原子可以出现为-CH═CH-或-C≡C-，并且该基团X未被取代或被取代为-COO-W或CONH-W; Q是一个残基-V-A1-L-A2-W或，如果X不表示键，则也可以是-NR6R7; V是一个双价芳香或杂环基团; W是芳基或杂环基团; 或在一个组-V-A1-L-A2-W中，其中至少有一个A1；L或A2也可能是一个单价取代或未取代的饱和或不饱和线性基团，其中最多有5个原子，包括C，N，O和/或S，其中一个碳可以出现为CO基团，一个硫原子可以出现为SO2基团，A1，A2彼此独立地不存在或是C1-C4烷基基团; L是-O-，-S-，-SO2-，-NH-，-CO-，-(CO)O-，-O(OC)-，-(CO)NH-，-NH(CO)-，-(SO2)NH-，-HN(SO2)-，-HN(CO)NH-，-O(CO)NH-，-NH(CO)O-，或者如果A1和/或A2存在，则L也可以不存在; R2是氢，R3是OR4或R2，R3共同形成一个C═O基团; R4是氢或含有1到6个碳原子的饱和或不饱和脂肪基团; R6，R7独立地选自芳基；芳基烷基；杂环基和杂环基烷基；其中R6和R7中的一个也可以是一个-L-W基团; *表示一个手性中心，它是(R)或(S)形式。
• Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer
  作者：Qihua Zhu、Xueyan Wang、Yan Hu、Xiaorong He、Guoqing Gong、Yungen Xu

  DOI：10.1016/j.bmc.2015.09.026

  日期：2015.10

  A series of imidazo[4,5-c]pyridine-7-carboxamide derivatives as poly(ADP-ribose) polymerase (PARP) inhibitors have been developed. All target compounds were evaluated for their PARP-1 inhibitory activity and some were further assessed for cellular potency. These efforts led to identification of a novel PARP-1 inhibitor 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide 11a (XZ-120312). 11a displayed strong inhibition against the PARP-1 enzyme with an IC50 of 8.6 +/- 0.6 nM and excellent potentiation of temozolomide cytotoxicity in cancer cell lines SW-620, MDA-MB-468 and A549 by 4.0, 3.0 and 7.7 times, respectively. (c) 2015 Elsevier Ltd. All rights reserved.
• Koegl et al., Recueil des Travaux Chimiques des Pays-Bas, 1948, vol. 67, p. 29,37
  作者：Koegl et al.

  DOI：——

  日期：——